Asunto(s)
Proteínas Morfogenéticas Óseas/metabolismo , Melanoma/genética , Cresta Neural/crecimiento & desarrollo , Neoplasias Cutáneas/genética , Adulto , Anciano , Anciano de 80 o más Años , Animales , Animales Modificados Genéticamente , Biopsia , Proteínas Morfogenéticas Óseas/genética , Embrión no Mamífero , Femenino , Regulación del Desarrollo de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Melanoma/patología , Persona de Mediana Edad , Modelos Animales , Transducción de Señal/genética , Piel/patología , Neoplasias Cutáneas/patología , Pez CebraRESUMEN
Preventing terminal differentiation is important in the development and progression of many cancers including melanoma. Recent identification of the BMP ligand GDF6 as a novel melanoma oncogene showed GDF6-activated BMP signaling suppresses differentiation of melanoma cells. Previous studies have identified roles for GDF6 orthologs during early embryonic and neural crest development, but have not identified direct regulation of melanocyte development by GDF6. Here, we investigate the BMP ligand gdf6a, a zebrafish ortholog of human GDF6, during the development of melanocytes from the neural crest. We establish that the loss of gdf6a or inhibition of BMP signaling during neural crest development disrupts normal pigment cell development, leading to an increase in the number of melanocytes and a corresponding decrease in iridophores, another neural crest-derived pigment cell type in zebrafish. This shift occurs as pigment cells arise from the neural crest and depends on mitfa, an ortholog of MITF, a key regulator of melanocyte development that is also targeted by oncogenic BMP signaling. Together, these results indicate that the oncogenic role ligand-dependent BMP signaling plays in suppressing differentiation in melanoma is a reiteration of its physiological roles during melanocyte development.
Asunto(s)
Proteínas Morfogenéticas Óseas/genética , Factor 6 de Diferenciación de Crecimiento/genética , Melanocitos/metabolismo , Factor de Transcripción Asociado a Microftalmía/genética , Proteínas de Pez Cebra/genética , Animales , Proteínas Morfogenéticas Óseas/antagonistas & inhibidores , Diferenciación Celular/genética , Regulación del Desarrollo de la Expresión Génica/genética , Humanos , Ligandos , Melanocitos/patología , Neoplasias/genética , Neoplasias/patología , Cresta Neural/crecimiento & desarrollo , Cresta Neural/metabolismo , Pigmentación/genética , Transducción de Señal/genética , Pez Cebra/genética , Pez Cebra/crecimiento & desarrolloRESUMEN
Oncogenomic studies indicate that copy number variation (CNV) alters genes involved in tumor progression; however, identification of specific driver genes affected by CNV has been difficult, as these rearrangements are often contained in large chromosomal intervals among several bystander genes. Here, we addressed this problem and identified a CNV-targeted oncogene by performing comparative oncogenomics of human and zebrafish melanomas. We determined that the gene encoding growth differentiation factor 6 (GDF6), which is the ligand for the BMP family, is recurrently amplified and transcriptionally upregulated in melanoma. GDF6-induced BMP signaling maintained a trunk neural crest gene signature in melanomas. Additionally, GDF6 repressed the melanocyte differentiation gene MITF and the proapoptotic factor SOX9, thereby preventing differentiation, inhibiting cell death, and promoting tumor growth. GDF6 was specifically expressed in melanomas but not melanocytes. Moreover, GDF6 expression levels in melanomas were inversely correlated with patient survival. Our study has identified a fundamental role for GDF6 and BMP signaling in governing an embryonic cell gene signature to promote melanoma progression, thus providing potential opportunities for targeted therapy to treat GDF6-positive cancers.
